Giulia Cucchetto

Verona, 37126, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational Study.

Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational Study.

Journal: Journal of clinical medicine

Published: April 22, 2025

COVID-19 in people with Cystic Fibrosis beyond the pre-omicron era: a prospective study with a specific focus on long COVID.

COVID-19 in people with Cystic Fibrosis beyond the pre-omicron era: a prospective study with a specific focus on long COVID.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: January 31, 2025

Long-term clinical outcomes of elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis and advanced pulmonary disease.

Long-term clinical outcomes of elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis and advanced pulmonary disease.

Journal: Respiratory medicine

Published: June 12, 2023

Immunogenicity and Safety of the BNT162b2 COVID-19 Vaccine in Patients with Cystic Fibrosis with or without Lung Transplantation.

Immunogenicity and Safety of the BNT162b2 COVID-19 Vaccine in Patients with Cystic Fibrosis with or without Lung Transplantation.

Journal: International journal of molecular sciences

Published: December 02, 2022

SARS-CoV-2 related pneumonia in an adult with cystic fibrosis: natural favourable clinical course or effective therapy?

SARS-CoV-2 related pneumonia in an adult with cystic fibrosis: natural favourable clinical course or effective therapy?

Journal: Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace

Published: August 20, 2020

High-dose or multi-day praziquantel for imported schistosomiasis? A systematic review.

High-dose or multi-day praziquantel for imported schistosomiasis? A systematic review.

Journal: Journal of travel medicine

Published: February 04, 2019

Darunavir/ritonavir 600/100 mg once daily: it's time for larger non-inferiority randomized trials.

Darunavir/ritonavir 600/100 mg once daily: it's time for larger non-inferiority randomized trials.

Journal: The Journal of antimicrobial chemotherapy

Published: April 03, 2018

Dolutegravir monotherapy in HIV-1-suppressed patients: A feasible regimen in real life.

Dolutegravir monotherapy in HIV-1-suppressed patients: A feasible regimen in real life.

Journal: International journal of STD & AIDS

Published: January 12, 2018

Dual therapy with a combination of unboosted atazanavir and lamivudine as maintenance treatment in virologically suppressed HIV-1-infected patients.

Dual therapy with a combination of unboosted atazanavir and lamivudine as maintenance treatment in virologically suppressed HIV-1-infected patients.

Journal: HIV medicine

Published: May 16, 2017

Raltegravir plus lamivudine as 'maintenance therapy' in suppressed HIV-1-infected patients in real-life settings.

Raltegravir plus lamivudine as 'maintenance therapy' in suppressed HIV-1-infected patients in real-life settings.

Journal: The Journal of antimicrobial chemotherapy

Published: April 19, 2017

Dolutegravir monotherapy in HIV-infected naive patients with an HIV-RNA load <100 000 copies/mL: a medium-term follow-up.

Dolutegravir monotherapy in HIV-infected naive patients with an HIV-RNA load <100 000 copies/mL: a medium-term follow-up.

Journal: The Journal of antimicrobial chemotherapy

Published: April 08, 2017

Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient.

Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient.

Journal: International journal of STD & AIDS

Published: October 30, 2016

Showing 1-12 of 16

Last Updated: 09/26/2026